Silo Pharma
NASDAQ: SILOSarasota, US · Nevada corporation
Silo Pharma is a developmental-stage biopharmaceutical company (Nasdaq: SILO) developing novel formulations of traditional and psychedelic therapeutics for underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its pipeline includes programs for PTSD, fibromyalgia, Alzheimer's, and multiple sclerosis, pursued via the FDA 505(b)(2) pathway in collaboration with academic research partners.
Founders & leadership
EW
Eric WeisblumChief Executive Officer
DR
Daniel RyweckChief Financial Officer
LS
Leonard SchillerNamed on SEC filing
VP
Van ParkerNamed on SEC filing
Board
KM
Kevin MunozBoard director
WL
Wayne LinsleyBoard director
JP
Jeff PavellBoard director
Reported raises · per SEC filings
Form D private placements$15.2M disclosed across 7 of 9 rounds · 2018–2026
▶$4MraisedJul 2026 · 4 investors · PharmaceuticalsRule 506(b)
▶$4MraisedJul 2026 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eric WeisblumExecutive Officer, Director
- Daniel RyweckExecutive Officer
- Wayne LinsleyDirector
- Kevin MunozDirector
- Jeff PavellDirector
- Offering amount
- $4M
- Amount sold
- $4M
- Sales commissions
- $300K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2.3MraisedAug 2024 · 2 investors · PharmaceuticalsRule 506(b)
▶$2.3MraisedAug 2024 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin MunozDirector
- Eric WeisblumExecutive Officer, Director
- Daniel RyweckExecutive Officer
- Wayne LinsleyDirector
- Jeff PavellDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- Sales commissions
- $157.5K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2.1MraisedJun 2024 · 3 investors · PharmaceuticalsRule 506(b)
▶$2.1MraisedJun 2024 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeff PavellDirector
- Kevin MunozDirector
- Wayne LinsleyDirector
- Eric WeisblumExecutive Officer, Director
- Daniel RyweckExecutive Officer
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- Sales commissions
- $150K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jun 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$4.3MraisedFeb 2021 · 47 investors · PharmaceuticalsRule 506(b)
▶$4.3MraisedFeb 2021 · 47 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Wayne D. LinsleyDirector
- Kevin MunozDirector
- Eric WeisblumExecutive Officer, Director
- Offering amount
- $4.3M
- Amount sold
- $4.3M
- Sales commissions
- $404.4K
- Placement agents
- Katalyst Securities LLC, Bradley Woods & Co. Ltd.
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedMay 2020 · 46 investors · RetailingRule 506(b)
▶$2.4MraisedMay 2020 · 46 investors · Retailing
Rule 506(b)Officers, directors & promoters on the filing
- Wayne D. LinsleyDirector
- Eric WeisblumExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.4M
- Sales commissions
- $173.9K
- Placement agents
- The Special Equities Group, LLC a division of Bradley Woods & Co. Ltd., Katalyst Securities, LLC
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$115KraisedDec 2019 · 3 investors · RetailingRule 506(b)
▶$115KraisedDec 2019 · 3 investors · Retailing
Rule 506(b)Officers, directors & promoters on the filing
- Eric WeisblumExecutive Officer, Director
- Leonard SchillerDirector
- Joel StoneDirector
- Van ParkerDirector
- Offering amount
- $2M
- Amount sold
- $115K
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24.5KraisedDec 2018 · RetailingRule 506(b)
▶$24.5KraisedDec 2018 · Retailing
Rule 506(b)Officers, directors & promoters on the filing
- Eric WeisblumExecutive Officer, Director
- Leonard SchillerDirector
- Van ParkerDirector
- Offering amount
- $200K
- Amount sold
- $24.5K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Public13 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Tradingview13 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanks12 shared keywordsFinancial analysis and stock research platform.
Simply Wall St11 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
StockTwits11 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.
Robinhood11 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha11 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Kraken9 shared keywordsKraken 360 Investments provides capital and launch infrastructure to blockchain protocols in pre-token and early post-token phases, offering custody, staking, treasury, and liquidity services alongside fundraising support.
Companies competing with Silo Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Silo Pharma AI Platform Launch Expected Within 90 Days | SILO Stock Newsstocktitan.net · Jul 2026
Silo Pharma (SILO) Stock Drops 28% Following $4M Financing Agreement - MoneyCheckmoneycheck.com · Jul 2026Frequently asked questions
- What does Silo Pharma do?
- Silo Pharma is a developmental-stage biopharmaceutical company (Nasdaq: SILO) developing novel formulations of traditional and psychedelic therapeutics for underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its pipeline includes programs for PTSD, fibromyalgia, Alzheimer's, and multiple sclerosis, pursued via the FDA 505(b)(2) pathway in collaboration with academic research partners.
- Who founded Silo Pharma?
- Silo Pharma was founded by Eric Weisblum.
- How much funding has Silo Pharma raised?
- Silo Pharma has disclosed $15.2M raised across 7 of its 9 known rounds.
- Where is Silo Pharma headquartered?
- Silo Pharma is headquartered in Sarasota, US.